Karakoz Mussabay

Karakoz Mussabay


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2024 in Viruses
Verified
Journal Article
Open access
PDF file
KMKarakoz Mussabay
Karakoz Mussabay
SKSamat Kozhakhmetov
Samat Kozhakhmetov
MDMarat Dusmagambetov
Marat Dusmagambetov
AMAitolkyn Mynzhanova
Aitolkyn Mynzhanova
MNMadiyar Nurgaziyev
Madiyar Nurgaziyev
AKAlmagul Kushugulova
Almagul Kushugulova
Recent studies highlight the crucial role of the gut microbiome in post-infectious complications, especially in patients recovering from severe COVID-19. Our research aimed to explore the connection between gut microbiome changes and the cytokine profile of patients with post-COVID syndrome. Using 16S rRNA amplicon sequencing, we analyzed the composition of the gut microbiome in 60 COVID-19 patients over the course of one year. We also measured the levels of serum cytokines and chemokines using the Milliplex system. Our results showed that severe SARS-CoV-2 infection cases, especially those complicated by pneumonia, induce a pro-inflammatory microbial milieu with heightened presence of Bacteroides, Faecalibacterium, and Prevotella_9. Furthermore, we found that post-COVID syndrome is characterized by a cross-correlation of various cytokines and chemokines MDC, IL-1b, Fractalkine, TNFa, FGF-2, EGF, IL-1RA, IFN-a2, IL-10, sCD40L, IL-8, Eotaxin, IL-12p40, and MIP-1b as well as a shift in the gut microbiome towards a pro-inflammatory profile. At the functional level, our analysis revealed associations with post-COVID-19 in homolactic fermentation, pentose phosphate, NAD salvage, and flavin biosynthesis. These findings highlight the intricate interplay between the gut microbiota, their metabolites, and systemic cytokines in shaping post-COVID symptoms. Unraveling the gut microbiome’s role in post-infectious complications opens avenues for new treatments for those patients with prolonged symptoms.

14 October 2024 in Therapy
Verified
Journal Article
Closed access
KMKarakoz Mussabay
Karakoz Mussabay
EVElizaveta Vinogradova
Elizaveta Vinogradova
MDMarat Dusmagambetov
Marat Dusmagambetov
BBBekbosynova M.S. Bekbosynova
Bekbosynova M.S. Bekbosynova
ATAinur T Tauekelova
Ainur T Tauekelova
ACAstana Heart Center
Astana Heart Center